Reference drug for BE [Design Issues]

posted by nguyenvo – 2006-06-13 23:11 (6497 d 23:55 ago) – Posting: # 145
Views: 9,483

Dear all,

If the original drug was withdrawn from market by the company, what should we choose as reference drug for a BE study?
We are studying BE/BA of 200 mg- cefixime capsule. The reference drug from Wyeth has already withdrawn from market. The another approved by FDA is Lupin (200 mg tablet)is not available.
We have some 200 mg cefixime capsules imported from India and Korea. Can I choose one of them as reference drug in my study and are there any other solutions for this problem?
In the same case, I would like to ask reference drug of gatifolaxin for BE study when Tequin would be withdrawn by Bristol Mayer Squibb?
I appreciate all your advice.

Nguyen Vo

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
90 visitors (0 registered, 90 guests [including 1 identified bots]).
Forum time: 22:07 CET (Europe/Vienna)

Nothing shows a lack of mathematical education more
than an overly precise calculation.    Carl Friedrich Gauß

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5